Differential expression, shedding, cytokine regulation and function of TNFR1 and TNFR2 in human fetal astrocytes

Tumor necrosis factor (TNF)-alpha induces pleiotropic cellular effects through a 55kDa, type 1 receptor (TNFR1) and a 75kDa type 2 receptor (TNFR2). Moreover, it participates in the pathogenesis of several CNS diseases, including demyelinating diseases. TNF-alpha receptors are differentially express...

Full description

Saved in:
Bibliographic Details
Published inYonsei medical journal Vol. 46; no. 6; pp. 818 - 826
Main Authors Choi, Sun Ju, Lee, Kyoung-Ho, Park, Hyun Sook, Kim, Soo-Ki, Koh, Choon-Myung, Park, Joo Young
Format Journal Article
LanguageEnglish
Published Korea (South) Yonsei University College of Medicine 31.12.2005
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Tumor necrosis factor (TNF)-alpha induces pleiotropic cellular effects through a 55kDa, type 1 receptor (TNFR1) and a 75kDa type 2 receptor (TNFR2). Moreover, it participates in the pathogenesis of several CNS diseases, including demyelinating diseases. TNF-alpha receptors are differentially expressed and are regulated in many cell types. However, data regarding the TNF-alpha receptor expression and regulation in human astrocytes is limited to date. We investigated TNF- receptor expression, its regulation by cytokines, and its functional role in primary cultured human fetal astrocytes, which are the most abundant cellular population in the central nervous system and are known to be immunologically active. In this study, astrocytes were found to constitutively and predominantly transcribe, translate and shed TNFR1 rather than TNFR2, but TNFR2 expression was increased by adding TNF-alpha, IL-1, and IFN-gamma, but not by adding LPS. To determine the functional roles of TNFR1 and TNFR2 on TNF induction, we investigated NF-kappaB activation and TNF-alpha induction after neutralizing TNFR1 and TNFR2 by an antibody treatment. We found that NF-kappaB activation and TNF-alpha induction are blocked by TNFR1 neutralizing antibody treatments.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0513-5796
1976-2437
DOI:10.3349/ymj.2005.46.6.818